Evidence map›Paper›PMID 33150791›Full record

ArticleCell transplantation

Production and Characterization of a Conditionally Immortalized Dog Beta-Cell Line from Fetal Canine Pancreas.

P Czernichow, K Reynaud, P Ravassard

Open access · goldAbstract read
In one paragraph

Article in Cell transplantation. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 43% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Immortalization Reversibility in the Context of Cell Therapy Biosafety.International journal of molecular sciences · 2023
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

P CzernichowAnimal Cell Therapy, Sorbonne Universités, Campus des Cordeliers, Paris, France.ORCID 0000-0002-0393-9262
K ReynaudEcole Nationale Vétérinaire d'Alfort, Maisons-Alfort, France.
P RavassardParis Brain Institute (ICM) Sorbonne Universités, Inserm, CNRS - Hôpital Pitié-Salpêtrière, Boulevard de l'Hôpital, Paris, France.
Centre National de la Recherche Scientifique · FRSorbonne Université · FR

Funding

Risks for HIV and STIs among Moscow Sex WorkersR01DA015005 · NIDA · JOHNS HOPKINS UNIVERSITY · PI BEYRER, CHRIS · 2002 to 2005
$1.4M
NIDA NIH HHS R01 DA015005
6 · The paper itself

Abstract

Since the 1970s, rodent and human insulin-secreting pancreatic beta-cell lines have been developed and found useful for studying beta-cell biology. Surprisingly, although the dog has been widely used as a translational model for diabetes, no canine insulin-secreting beta cells have ever been produced. Here, a targeted oncogenesis protocol previously described by some of us for generating human beta cells was adapted to produce canine beta cells. Canine fetal pancreata were obtained by cesarean section between 42 and 55 days of gestation, and fragments of fetal glands were transduced with a lentiviral vector expressing SV40LT under the control of the insulin promoter. Two Lox P sites flanking the sequence allowed subsequent transgene excision by Cre recombinase expression. When grafted into SCID mice, these transduced pancreata formed insulinomas. ACT-164 is the cell line described in this report. Insulin mRNA expression and protein content were lower than reported with adult cells, but the ACT-164 cells were functional, and their insulin production

Indexed as

AnimalsCell ProliferationDogsFemaleInsulinInsulinomaInsulin-Secreting CellsIntegrasesMice, SCIDPancreasPregnancyPromoter Regions, GeneticRNA, MessengerCre recombinaseInsulinIntegrasesRNA, Messengerbeta-cell lineconditional immortalizationdiabetesdogtranslational model

Identifiers

PMID33150791
PMCPMC7784601
OpenAlexW3095662832

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.